Trial Profile
A prospective study evaluating the efficacy and safety of Aflibercept in patients with treatment-naive polypoidal choroidal vasculopathy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Dec 2015
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Polypoidal choroidal vasculopathy
- Focus Therapeutic Use
- 04 Dec 2015 New trial record
- 01 Nov 2014 According to the results published, the patients were enrolled between February 2013 and July 2013.